JLB & Associates Inc. Sells 980 Shares of Stryker Co. (NYSE:SYK)

JLB & Associates Inc. lowered its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 3.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,925 shares of the medical technology company's stock after selling 980 shares during the quarter. JLB & Associates Inc.'s holdings in Stryker were worth $10,395,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Capital & Planning LLC lifted its stake in Stryker by 3.6% in the fourth quarter. Capital & Planning LLC now owns 841 shares of the medical technology company's stock valued at $304,000 after buying an additional 29 shares during the period. Brighton Jones LLC grew its holdings in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after purchasing an additional 609 shares during the period. Van ECK Associates Corp grew its holdings in Stryker by 1.3% in the fourth quarter. Van ECK Associates Corp now owns 13,035 shares of the medical technology company's stock worth $4,693,000 after purchasing an additional 173 shares during the period. Aveo Capital Partners LLC bought a new stake in Stryker in the fourth quarter valued at $290,000. Finally, Principal Securities Inc. raised its holdings in shares of Stryker by 21.5% during the fourth quarter. Principal Securities Inc. now owns 7,584 shares of the medical technology company's stock valued at $2,731,000 after purchasing an additional 1,340 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 5.90% of the company's stock.

Stryker Stock Performance

Shares of SYK traded down $3.76 on Tuesday, reaching $373.36. 1,338,060 shares of the company's stock traded hands, compared to its average volume of 1,331,450. The stock's 50 day simple moving average is $373.53 and its two-hundred day simple moving average is $375.55. The stock has a market cap of $142.51 billion, a PE ratio of 48.11, a PEG ratio of 2.93 and a beta of 0.91. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business's revenue was up 11.9% compared to the same quarter last year. During the same period last year, the firm posted $2.50 EPS. On average, analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date is Monday, June 30th. Stryker's payout ratio is 45.41%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Citigroup restated a "buy" rating and issued a $455.00 target price (up from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. BTIG Research set a $403.00 price target on Stryker and gave the stock a "buy" rating in a report on Monday, April 14th. Evercore ISI decreased their price objective on Stryker from $400.00 to $390.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. JMP Securities reiterated a "market perform" rating on shares of Stryker in a report on Monday, May 5th. Finally, Sanford C. Bernstein set a $450.00 price target on shares of Stryker in a research report on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $427.30.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.